Skip to main content
. 2004 Mar 1;141(6):1024–1031. doi: 10.1038/sj.bjp.0705694

Figure 2.

Figure 2

AT1 receptor-mediated increases in UA cyclic GMP content, demonstrated by the combination of PD 123319 (1 μM) plus Ang II (10 nmol/l) (n=8). Effect of pretreatment with either NOLA (30 μM) (n=6), HOE 140 (0.1 μM) (n=6) or the combination of HOE 140 (0.1 μM) plus losartan (0.1 μM) (n=5), and the effect of HOE 140 plus PD 123319 on basal UA cyclic GMP levels (n=5). *P<0.05, ***P<0.001 versus control; †P<0.05, †††P<0.001 versus PD 123319 plus Ang II; ‡‡‡P<0.001 versus HOE 140 plus PD 123319 plus Ang II (one-way ANOVA).